Top

Published in:

28-07-2023 | Radiotherapy | REVIEW ARTICLE

Hype or hope? A review of challenges in balancing tumor control and treatment toxicity in breast cancer from the perspective of the radiation oncologist

Authors: Javier González-Viguera, Evelyn Martínez-Pérez, Héctor Pérez-Montero, Marina Arangüena, Ferran Guedea, Cristina Gutiérrez-Miguélez

Published in: Clinical and Translational Oncology | Issue 3/2024

Abstract

The aim of this article is to discuss the challenges and new strategies in managing breast cancer patients, with a specific focus on radiation oncology and the importance of balancing oncologic outcomes with quality of life and post-treatment morbidity. A comprehensive literature review was conducted to identify advances in the management of breast cancer, exploring de-escalation strategies, hypofractionation schemes, predictors and tools for reducing toxicity (radiation-induced lymphocyte apoptosis, deep inspiration breath-hold, adaptive radiotherapy), enhancer treatments (hyperthermia, immunotherapy) and innovative diagnostic modalities (PET-MRI, omics). Balancing oncologic outcomes with quality of life and post-treatment morbidity is crucial in the era of personalized medicine. Radiotherapy plays a critical role in the management of breast cancer patients. Large randomized trials are necessary to generalize some practices and cost remains the main obstacle for many innovations that are already applicable.

Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun (Lond). 2022;42(10):913–36. https://doi.org/10.1002/cac2.12358.CrossRefPubMed

Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death. meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group); McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality. meta-analysis of individual patient data for 8135 women in 22 randomised trials [published correction appears in Lancet. 2014 Nov 22;384(9957):1848]. Lancet. 2014;383(9935):2127–35. https://doi.org/10.1016/S0140-6736(14)60488-8.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer. 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94. https://doi.org/10.1016/S1470-2045(13)70386-3.

Offersen BV, Alsner J, Nielsen HM, Jakobsen E, Nielsen M, Krause M, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615–25. https://doi.org/10.1200/JCO.20.01363.CrossRefPubMed

Whelan TJ, Pignol JP, Levine MN, Julian J, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20. https://doi.org/10.1056/NEJMoa0906260.CrossRefPubMed

Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward). 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–26. https://doi.org/10.1016/S0140-6736(20)30932-6.

Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. european society for radiotherapy and oncology advisory committee in radiation oncology practice consensus recommendations, n patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23(1):e21–31. https://doi.org/10.1016/S1470-2045(21)00539-8.CrossRefPubMed

Meattini I, Guenzi M, Fozza A, Vidali C, Rovea P, Meacci F, et al. Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer. Breast Cancer. 2017;24(1):52–62. https://doi.org/10.1007/s12282-016-0694-3.CrossRefPubMed

10.

Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656–65. https://doi.org/10.1016/j.ijrobp.2009.09.064.CrossRefPubMedPubMedCentral

11.

Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007;7:9. https://doi.org/10.1186/1471-240.CrossRefPubMedPubMedCentral

12.

Haussmann J, Corradini S, Nestle-Kraemling C, Bölke E, Njanang FJD, Tamaskovics B, et al. Recent advances in radiotherapy of breast cancer. Radiat Oncol. 2020;15(1):71. https://doi.org/10.1186/s13014-020-01501-x.CrossRefPubMedPubMedCentral

13.

Fastner G, Reitsamer R, Gaisberger C, Stana M, Sedlmayer F. Intraoperative partial breast irradiation with electrons (ELIOT) compared to conventionally fractionated whole-breast irradiation of early-stage invasive breast cancer after: breast-conserving surgery: long-term data from a prospective randomised trial. Strahlenther Onkol. 2021;197(11):1032–6. https://doi.org/10.1007/s00066-021-01848-4.CrossRefPubMed

14.

Vaidya JS, Bulsara M, Wenz F, Sperk E, Massarut S, Alvarado M, et al. The TARGIT-a randomized trial: TARGIT-IORT Versus whole breast radiation therapy. long-term local control and survival. Int J Radiat Oncol Biol Phys. 2023;115(1):77–82. https://doi.org/10.1016/j.ijrobp.2022.08.029.

15.

Liu G, Dong Z, Huang B, Liu Y, Tang Y, Li Q, et al. Efficacy and safety of accelerated partial breast irradiation: a meta-analysis of published randomized studies. Oncotarget. 2017;8(35):59581–91. https://doi.org/10.18632/oncotarget.19225.CrossRefPubMedPubMedCentral

16.

Fastner G, Gaisberger C, Kaiser J, Scherer P, Ciabattoni A, Petoukhova A, et al. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer. Radiother Oncol. 2020;149:150–7. https://doi.org/10.1016/j.radonc.2020.04.05.CrossRefPubMed

17.

Schäfer R, Strnad V, Polgár C, Uter W, Hildebrandt G, Ott OJ, et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer, after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncol. 2018;19(6):834–44. https://doi.org/10.1016/S1470-2045(18)30195-5.CrossRefPubMed

18.

Guinot JL, Gonzalez-Perez V, Meszaros N, Major T, Najjari-Jamal D, Gutierrez-Miguelez C, et al. Very accelerated partial breast irradiation Phase I-II multicenter trial (VAPBI): feasibility and early results. Brachytherapy. 2021;20(2):332–8. https://doi.org/10.1016/j.brachy.2020.10.010.CrossRefPubMed

19.

Hannoun-Lévi JM, Montagne L, Sumodhee S, Schiappa R, Boulahssass R, Gautier M, et al. APBI versus ultra-APBI in the elderly with low-risk breast cancer: a comparative analysis of oncological outcome and late toxicity. Int J Radiat Oncol Biol Phys. 2021;111(1):56–67. https://doi.org/10.1016/j.ijrobp.2021.03.052.CrossRefPubMed

20.

Strnad V, Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, et al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer. 10-year results of a GEC-ESTRO randomised, phase 3 non-inferiority trial. Lancet Oncol. 2023;24(3):262–272. https://doi.org/10.1016/S1470-2045(23)00018-9.

21.

Meattini I, Marrazzo L, Saieva C, Desideri I, Scotti V, Simontacchi G, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer. long-term results of the randomized phase III APBI-IMRT-florence trial. J Clin Oncol. 2020;38(35):4175–83. https://doi.org/10.1200/JCO.20.00650.

22.

Ciérvide R, Montero Á, Potdevin G, García J , Aranda MG, Álvarez B, et al. 5-year results of accelerated partial breast irradiation (APBI) with SBRT (stereotactic body radiation therapy), and exactrac adaptive gating (Novalis®) for very early breast cancer patients: was it all worth it? Clin Transl Oncol. 2021;23(11):2358–67. https://doi.org/10.1007/s12094-021-02636-3.

23.

Guidolin K, Yaremko B, Lynn K, Gaede S, Kornecki A, Muscedere G, et al. Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the SIGNAL prospective single-arm trial of single-dose radiation therapy. Curr Oncol. 2019;26(3):334–40. https://doi.org/10.3747/co.26.4479.CrossRefPubMedPubMedCentral

24.

Li YR, Barry PN. Pre-operative partial breast irradiation: revolutionizing radiation treatment for women with early stage breast cancer. Ann Breast Surg. 2022;6:38. https://doi.org/10.21037/abs-20-133.CrossRefPubMedPubMedCentral

25.

Senkus E, Cardoso MJ, Kaidar-Person O, Łacko A, Meattini I, Poortmans P. De-escalation of axillary irradiation for early breast cancer—Has the time come?. Cancer Treat Rev. 2021;101:102297. https://doi.org/10.1016/j.ctrv.2021.102297.

26.

de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022;23(9):1201–10. https://doi.org/10.1016/S1470-2045(22)00482-X.CrossRefPubMed

27.

Rusthoven CG, Rabinovitch RA, Jones BL, Koshy M, Amini A, Yeh N, et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer. a National Cancer Database (NCDB) analysis. Ann Oncol. 2016;27(5):818–827. doi:https://doi.org/10.1093/annonc/mdw046.

28.

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015;261(3):547–52. https://doi.org/10.1097/SLA.0000000000000551.CrossRefPubMed

29.

Fayanju OM, Ren Y, Suneja G, Thomas SM, Greenup RA, Plichta JK, et al. Nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy after breast cancer diagnosis. Int J Radiat Oncol Biol Phys. 2020;106(2):377–89. https://doi.org/10.1016/j.ijrobp.2019.10.039.CrossRefPubMed

30.

Daveau C, Stevens D, Brain E, Berges O, Villette S, Moisson P, et al. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy? Int J Radiat Oncol Biol Phys. 2010;78(2):337–42. https://doi.org/10.1016/j.ijrobp.2009.08.053.CrossRefPubMed

31.

Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12–05). Int J Radiat Oncol Biol Phys. 2014;88(1):65–72. https://doi.org/10.1016/j.ijrobp.2013.09.021.CrossRefPubMed

32.

Liu J, Mao K, Jiang S, Jiang W, Chen K, Kim BY, et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy. an analysis from the NCDB. Oncotarget. 2016;7(17):24848–24859. https://doi.org/10.18632/oncotarget.6664

33.

Kantor O, Pesce C, Singh P, Miller M, Tseng J, Wang CH, et al. Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy. J Surg Oncol. 2017;115(6):668–76. https://doi.org/10.1002/jso.24551.CrossRefPubMed

34.

Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer JU, et al. Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials. Ann Surg Oncol. 2019;26(12):3892–901. https://doi.org/10.1245/s10434-019-07635-x.CrossRefPubMed

35.

Rong QL, Wang SL, Tang Y, Jin J, Song YW, Wang WH, et al. The role of postmastectomy radiotherapy in clinical T1–3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy. The role of postmastectomy radiotherapy in clinical T1–3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy. Chin J Oncol. 2017;39(6):445–452. doi:https://doi.org/10.3760/cma.j.issn.0253-3766.201

36.

Le Scodan R, Selz J, Stevens D, Bollet MA, de la Lande B, Daveau C, et al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2012;82(1):e1–7. https://doi.org/10.1016/j.ijrobp.2010.12.054.CrossRefPubMed

37.

McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–9. https://doi.org/10.1016/j.ijrobp.2007.01.023.CrossRefPubMedPubMedCentral

38.

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery study at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01872975.

39.

Bazan JG, Jhawar SR, Stover D, Park KU, Beyer S, Healy E, et al. De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer. NPJ Breast Cancer. 2021;7(1):33. https://doi.org/10.1038/s41523-021-00242-8.CrossRefPubMedPubMedCentral

40.

Haque W, Verma V, Hsiao KY, Hatch S, Arentz C, Szeja S, et al. Omission of radiation therapy following breast conservation in older (≥70 years) women with T1–2N0 triple-negative breast cancer. Breast J. 2019;25(6):1126–33. https://doi.org/10.1111/tbj.13443.CrossRefPubMed

41.

Herskovic AC, Wu X, Christos PJ, Nagar H. Omission of adjuvant radiotherapy in the elderly breast cancer patient: missed opportunity? Clin Breast Cancer. 2018;18(5):418–31. https://doi.org/10.1016/j.clbc.2018.02.006.CrossRefPubMed

42.

Wu SG, Li FY, Wang J, Lian CL, Zhou J, He ZY. Omission of adjuvant radiotherapy following breast-conserving surgery for elderly women with early-stage pure mucinous breast carcinoma. Radiat Oncol. 2019;14(1):190. https://doi.org/10.1186/s13014-019-1394-x.CrossRefPubMedPubMedCentral

43.

Franco P, Iorio GC, Bartoncini S, Airoldi M, De Sanctis C, Castellano I, et al. De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients. Med Oncol. 2018;35(5):62. https://doi.org/10.1007/s12032-018-1121-8.CrossRefPubMed

44.

The IDEA (Individualized Decisions for Endocrine therApy) study at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02400190.

45.

The PRECISION (Profiling Early Breast Cancer for Radiotherapy Omission) trial at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02653755.

46.

A prospective cohort study evaluating risk of local recurrence following breast conserving surgery and endocrine therapy in low risk LUMINAL A Breast cancer (LUMINA) at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01791829.

47.

Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20(20):4141–9. https://doi.org/10.1200/JCO.2002.11.101.CrossRefPubMed

48.

Winzer KJ, Sauer R, Sauerbrei W, Schneller E, Jaeger W, Braun M, et al. Radiation therapy after breast-conserving surgery; first results of a randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2004;40(7):998–1005. https://doi.org/10.1016/j.ejca.2004.01.007.CrossRefPubMed

49.

Blamey RW, Bates T, Chetty U, Duffy SW, Ellis IO, George D, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British association of surgical oncology (BASO) II trial. Eur J Cancer. 2013;49(10):2294–302. https://doi.org/10.1016/j.ejca.2013.02.031.CrossRefPubMed

50.

Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963–70. https://doi.org/10.1056/NEJMoa040595.CrossRefPubMed

51.

Tinterri C, Gatzemeier W, Costa A, Gentilini MA, Zanini V, Regolo L, et al. Breast-conservative surgery with and without radiotherapy in patients, aged 55–75 years with early-stage breast cancer: a prospective, randomized, multicenter trial analysis after 108 months of median follow-up. Ann Surg Oncol. 2014;21(2):408–15. https://doi.org/10.1245/s10434-013-3233-x.CrossRefPubMed

52.

Pötter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68(2):334–40. https://doi.org/10.1016/j.ijrobp.2006.12.045.CrossRefPubMed

53.

Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7. https://doi.org/10.1200/JCO.2012.45.2615.CrossRefPubMedPubMedCentral

54.

Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in early breast cancer. N Engl J Med. 2023;388(7):585–94. https://doi.org/10.1056/NEJMoa2207586.CrossRefPubMed

55.

Meattini I, Poortmans PMP, Marrazzo L, Desideri I, Brain E, Hamaker M, et al. Exclusive endocrine therapy or partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598—EUROPA). Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. J Geriatr Oncol. 2021;12(2):182–9. https://doi.org/10.1016/j.jgo.2020.07.013.

56.

Schmitt M, Menoux I, Chambrelant I, Hild C, Petit T, Mathelin C, et al. Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: a systematic literature review. Transl Oncol. 2022;22:101456. https://doi.org/10.1016/j.tranon.2022.101456.

57.

Coles CE, Haviland JS, Kirby AM, Griffin CL, Sydenham MA, Titley JC, et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet. 2023;401(10394):2124–37. https://doi.org/10.1016/S0140-6736(23)00619-0.CrossRefPubMed

58.

Monten C, Lievens Y, Olteanu LAM, Paelinck L, Speleers B, Deseyne P, et al. Highly accelerated irradiation in 5 fractions (HAI-5): feasibility in elderly women with early or locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017;98(4):922–30. https://doi.org/10.1016/j.ijrobp.2017.01.229.CrossRefPubMed

59.

Van Hulle H, Vakaet V, Deckmyn K, Monten C, Paelinck L, Van Greveling A, et al. Two-year toxicity of hypofractionated breast cancer radiotherapy in five fractions. Acta Oncol. 2020;59(7):872–5. https://doi.org/10.1080/0284186X.2020.1747638.CrossRefPubMed

60.

Yarnold J. Changes in radiotherapy fractionation-breast cancer. Br J Radiol. 2019;92(1093):20170849. https://doi.org/10.1259/bjr.20170849.CrossRefPubMed

61.

Van Hulle H, Vakaet V, Monten C, Deseyne P, Schoepen M, Colman C, et al. Acute toxicity and health-related quality of life after accelerated whole breast irradiation in 5 fractions with simultaneous integrated boost. Breast. 2021;55:105–11. https://doi.org/10.1016/j.breast.2020.12.009.CrossRefPubMed

62.

Van Hulle H, Vakaet V, Post G, Van Greveling A, Monten C, Hendrix A, et al. Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients. Pilot Feasibility Stud. 2020;6:154. https://doi.org/10.1186/s40814-020-00693-z.CrossRefPubMedPubMedCentral

63.

Azria D, Riou O, Castan F, Nguyen TD, Peignaux K, Lemanski C, et al. Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of breast fibrosis after radiotherapy: results of the prospective multicenter french trial. EBioMedicine. 2015;2(12):1965–73. https://doi.org/10.1016/j.ebiom.2015.10.024.CrossRefPubMedPubMedCentral

64.

Lapierre A, Bourillon L, Larroque M, Gouveia T, Bourgier C, Ozsahin M, et al. Improving patients’ life quality after radiotherapy treatment by predicting late toxicities. Cancers (Basel). 2022;14(9):2097. https://doi.org/10.3390/cancers14092097.CrossRefPubMed

65.

Díaz-Gavela AA, Figueiras-Graillet L, Luis ÁM, Salas Segura J, Ciérvide R, Del Cerro Peñalver E, et al. Breast radiotherapy-related cardiotoxicity. when, how, why. risk prevention and control strategies. Cancers (Basel). 2021;13(7):1712. https://doi.org/10.3390/cancers13071712.

66.

Milo MLH, Thorsen LBJ, Johnsen SP, Nielsen KM, Valentin JB, Alsner J, et al. Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: a population-based Danish Breast Cancer Group study. Radiother Oncol. 2021;157:106–13. https://doi.org/10.1016/j.radonc.2021.01.010.CrossRefPubMed

67.

De-Colle C, Kirby A, Russell N, Shaitelman SF, Currey A, Donovan E,, et al. Adaptive radiotherapy for breast cancer. Clin Transl Radiat Oncol. 2022;39:100564. https://doi.org/10.1016/j.ctro.2022.100564.

68.

Luo W, Ali YF, Liu C, Wang Y, Liu C, Jin X, et al. Particle therapy for breast cancer: benefits and challenges. Front Oncol. 2021;11:662826. https://doi.org/10.3389/fonc.2021.662826.

69.

MacDonald SM, Patel SA, Hickey S, Specht M, Isakoff SJ, Gadd M, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013;86(3):484–90. https://doi.org/10.1016/j.ijrobp.2013.01.038.CrossRefPubMed

70.

Fattahi S, Ahmed SK, Park SS, Petersen IA, Shumway DA, Stish BJ, et al. Reirradiation for locoregional recurrent breast cancer. Adv Radiat Oncol. 2021. https://doi.org/10.1016/j.adro.2020.100640.CrossRefPubMed

71.

Oldenborg S, Griesdoorn V, Rv Os, Kusumanto YH, Oei BS, Venselaar JL, et al. Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: size matters. Radiother Oncol 2015;117(2):223–8. https://doi.org/10.1016/j.radonc.2015.10.017.

72.

Datta NR, Puric E, Klingbiel D, Gomez S, Bodis S. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(5):1073–87. https://doi.org/10.1016/j.ijrobp.2015.12.361.CrossRefPubMed

73.

Bakker A, Tello Valverde CP, van Tienhoven G, Kolff MW, Kok HP, Slotman BJ, et al. Post-operative re-irradiation with hyperthermia in locoregional breast cancer recurrence: temperature matters. Radiother Oncol. 2022;167:149–57. https://doi.org/10.1016/j.radonc.2021.12.036.CrossRefPubMed

74.

David S, Tan J, Siva S, Karroum L, Savas P, Loi S. Combining radiotherapy and immunotherapy in metastatic breast cancer: current status and future directions. Biomedicines. 2022;10(4):821. https://doi.org/10.3390/biomedicines10040821.CrossRefPubMedPubMedCentral

75.

Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer (STEREO-SEIN) at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02089100

76.

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/record/NCT02364557

77.

Krug D, Vonthein R, Illen A, Olbrich D, Barkhausen J, Richter J, et al. Metastases-directed radiotherapy in addition to standard systemic therapy in patients with oligometastatic breast cancer. study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021;28:90–96. https://doi.org/10.1016/j.ctro.2021.03.012

78.

Fowler AM, Strigel RM. Clinical advances in PET-MRI for breast cancer. Lancet Oncol. 2022;23(1):e32–43. https://doi.org/10.1016/S1470-2045(21)00577-5.CrossRefPubMedPubMedCentral

79.

Rossi C, Cicalini I, Cufaro MC, Consalvo A, Upadhyaya P, Sala G, et al. Breast cancer in the era of integrating “Omics” approaches. Oncogenesis. 2022;11(1):17. https://doi.org/10.1038/s41389-022-00393-8.CrossRefPubMedPubMedCentral

80.

Pesapane F, Rotili A, Agazzi GM, Botta F, Raimondi S, Penco S, et al. Recent radiomics advancements in breast cancer: lessons and pitfalls for the next future. Curr Oncol. 2021;28(4):2351–72. https://doi.org/10.3390/curroncol28040217.CrossRefPubMedPubMedCentral

81.

Tan H, Wu Y, Bao F, Zhou J, Wan J, Tian J, et al. Mammography-based radiomics nomogram: a potential biomarker to predict axillary lymph node metastasis in breast cancer. Br J Radiol. 2020;93(1111):20191019. https://doi.org/10.1259/bjr.20191019.CrossRefPubMedPubMedCentral

82.

Stelzer PD, Steding O, Raudner MW, Euller G, Clauser P, Baltzer PAT. Combined texture analysis and machine learning in suspicious calcifications detected by mammography: potential to avoid unnecessary stereotactical biopsies. Eur J Radiol. 2020;132:109309. https://doi.org/10.1016/j.ejrad.2020.109309.CrossRefPubMed

83.

Zhou J, Tan H, Bai Y, Li J, Lu Q, Ch R, et al. Evaluating the HER-2 status of breast cancer using mammography radiomics features. Eur J Radiol. 2019;121:108718. https://doi.org/10.1016/j.ejrad.2019.108718.CrossRefPubMed

84.

Lei C, Wei W, Liu Z, Xiong Q, Yang C, Yang M, et al. Mammography-based radiomic analysis for predicting benign BI-RADS category 4 calcifications. Eur J Radiol. 2019;121:108711. doi:https://doi.org/10.1016/j.ejrad.2019.108711.

85.

Lin F, Wang Z, Zhang K, Yang P, Ma H, Shi Y, et al. Contrast-enhanced spectral mammography-based radiomics nomogram for identifying benign and malignant breast lesions of sub-1 cm. Front Oncol. 2020;10:573630. https://doi.org/10.3389/fonc.2020.573630.CrossRefPubMedPubMedCentral

86.

Mao N, Yin P, Li Q, Wang Q, Liu M, Ma H, et al. Radiomics nomogram of contrast-enhanced spectral mammography for prediction of axillary lymph node metastasis in breast cancer: a multicenter study. Eur Radiol. 2020;30(12):6732–9. https://doi.org/10.1007/s00330-020-.CrossRefPubMed

87.

Tan H, Gan F, Wu Y, Zhou J, Tian J, Lin, et al. Preoperative prediction of axillary lymph node metastasis in breast carcinoma using radiomics features based on the fat-suppressed T2 sequence. Acad Radiol. 2020;27(9):1217–1225. https://doi.org/10.1016/j.acra.2019.11.004

88.

Choudhery S, Gomez-Cardona D, Favazza CP, Hoskin TL, Haddad TC, Goetz MP, et al. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Acad Radiol. 2022;29(Suppl 1):S145–54. https://doi.org/10.1016/j.acra.2020.10.020.CrossRefPubMed

89.

Hao W, Gong J, Wang S, Zhu H, Zhao B, Peng W. Application of MRI radiomics-based machine learning model to improve contralateral bi-rads 4 lesion assessment. Front Oncol. 2020;10:531476. https://doi.org/10.3389/fonc.2020.531476.CrossRefPubMedPubMedCentral

90.

Lo Gullo R, Daimiel I, Rossi Saccarelli C, Bitencourt A, Gibbs P, Fox MJ, et al. Improved characterization of sub-centimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers. Eur Radiol. 2020;30(12):6721–31. https://doi.org/10.1007/s00330-020-06991-7.CrossRefPubMedPubMedCentral

91.

Demircioglu A, Grueneisen J, Ingenwerth M, Hoffmann O, Pinker-Domenig K, Morris E, et al. A rapid volume of interest-based approach of radiomics analysis of breast MRI for tumor decoding and phenotyping of breast cancer. PLoS One. 2020;15(6):e0234871. https://doi.org/10.1371/journal.pone.0234871

92.

Zhang Q, Peng Y, Liu W, Bai J, Zheng J, Yan X, et al. Radiomics based on multimodal MRI for the differential diagnosis of benign and malignant breast lesions. J Magn Reson Imaging. 2020;52(2):596–607. https://doi.org/10.1002/jmri.27098.CrossRefPubMed

93.

Zhou J, Zhang Y, Chang KT, Lee KE, Wang O, Li J, et al. Diagnosis of benign and malignant breast lesions on DCE-MRI by using radiomics and deep learning with consideration of peritumor tissue. J Magn Reson Imaging. 2020;51(3):798–809. https://doi.org/10.1002/jmri.26981.CrossRefPubMed

94.

Liu Z, Feng B, Li C, Chen Y, Chen Q, Li X, et al. Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast-enhanced-MRI-based radiomics. J Magn Reson Imaging. 2019;50(3):847–57. https://doi.org/10.1002/jmri.26688.CrossRefPubMed

95.

Xie T, Wang Z, Zhao Q, Bai Q, Zhou X, Gu Y, et al. Machine learning-based analysis of MR multiparametric radiomics for the subtype classification of breast cancer. Front Oncol. 2019;9:505. https://doi.org/10.3389/fonc.2019.00505.CrossRefPubMedPubMedCentral

96.

Liang C, Cheng Z, Huang Y, He L, Chen X, Ma Z, et al. An MRI-based radiomics classifier for preoperative prediction of Ki-67 status in breast cancer. Acad Radiol. 2018;25(9):1111–7. https://doi.org/10.1016/j.acra.2018.01.006.CrossRefPubMed

97.

Ou X, Zhang J, Wang J, Pang F, Wang Y, Wei X, et al. Radiomics based on 18 F-FDG PET/CT could differentiate breast carcinoma from breast lymphoma using machine-learning approach: a preliminary study. Cancer Med. 2020;9(2):496–506. https://doi.org/10.1002/cam4.2711.CrossRefPubMed

Title: Hype or hope? A review of challenges in balancing tumor control and treatment toxicity in breast cancer from the perspective of the radiation oncologist
Authors: Javier González-Viguera
Evelyn Martínez-Pérez
Héctor Pérez-Montero
Marina Arangüena
Ferran Guedea
Cristina Gutiérrez-Miguélez
Publication date: 28-07-2023
Publisher: Springer International Publishing
Keywords: Radiotherapy
Breast Cancer
Breast Cancer
Published in: Clinical and Translational Oncology / Issue 3/2024
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03287-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

Analysis of the prognostic value of uric acid on the efficacy of immunotherapy in patients with primary liver cancer

CircRNA-regulated glucose metabolism in ovarian cancer: an emerging landscape for therapeutic intervention

Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma

The relationship between brain metastasis and HER2 expression status in gastric cancer

Pattern of practice of re-irradiation for ipsilateral breast tumor recurrence in Italy: a survey by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Palliative care for children with central nervous system tumors: results of a Spanish multicenter study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer